Drug Approval | February 16, 2023
Zydus receives tentative approval from the USFDA for Canagliflozin tablets
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
DETAF would be a welcome new addition in the management of HIV infections and will be available for supplies to low- and middle-income countries
Dolutegravir and Rilpivirine Tablets, 50 mg/25 mg, (RLD Juluca) had estimated annual sales of US $666 million in the US (IQVIA MAT September 2022)
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
The drug will be manufactured at the group's injectable manufacturing facility at Jarod, near Vadodara, India
Doxycycline Capsules (RLD Oracea) had estimated annual sales of US $215 million in the US
Drospirenone Tablets (RLD Slynd) had estimated annual sales of US $141 million in the US
Roflumilast Tablets had annual sales of US $248 million in the United States according to IQVIA data
Valbenazine Capsules had annual sales of US $781 million in the United States according to IQVIA data
Amantadine Extended-Release capsules had annual sales of US $2.7 million in the United States according to IQVIA data
Subscribe To Our Newsletter & Stay Updated
